Scleromalacia perforans is a rare eye problem that causes severe thinning of the white outer wall of the eye. It most often affects people living with long-standing rheumatoid arthritis, especially older adults, and the early symptoms of scleromalacia perforans may be very mild or absent. Many living with scleromalacia perforans have little pain, but a doctor may see dark areas where the eye wall has become very thin. The condition usually develops slowly over time, and not everyone will have the same experience. Scleromalacia perforans is not usually fatal on its own, but it needs prompt eye care and treatment of the underlying autoimmune disease, often with medicines that calm the immune system.
How many people live with Scleromalacia perforans?
Global and U.S. prevalence estimates for scleromalacia perforans, a very rare form of thinning of the white part of the eye, are not consistently reported by a single authoritative source. In other words, there is no recent, reliable estimate for how many people worldwide or in the United States are living with it.
Overview
Scleromalacia perforansSymptoms
Scleromalacia perforans often causes little or no pain, even as the white of the eye becomes thin and may look bluish or dark. Some people notice mild irritation, dryness, or changes in vision later on.
Outlook and prognosis
Scleromalacia perforans often progresses slowly but can quietly thin the white of the eye, raising the risk of severe damage or vision loss if not closely monitored. Outlook is best with regular eye care and treatment of the underlying autoimmune disease.
Causes and risk factors
Scleromalacia perforans is usually linked to longstanding rheumatoid arthritis and less often other autoimmune diseases. Risk is higher with severe poorly controlled inflammation, especially in older adults, particularly women, and in people with a history of related eye inflammation.
Genetic influences
Genetics are not thought to play a major direct role in scleromalacia perforans. It is usually linked to autoimmune disease, so inherited immune-system differences may slightly affect risk in some people.
Diagnosis
Scleromalacia perforans is diagnosed with an eye exam that looks for thinning of the white part of the eye. Doctors also review symptoms, medical history, and conditions such as rheumatoid arthritis. Imaging may help assess how deep the thinning is.
Treatment and drugs
Scleromalacia perforans treatment focuses on calming the underlying autoimmune disease, often with rheumatology-guided medicines. Eye doctors also protect the eye surface with lubricating drops and close monitoring. Severe thinning may need a tissue graft to strengthen the sclera.
Symptoms
Changes in the eye can be surprisingly quiet with scleromalacia perforans, so many people do not feel very sick even while damage is happening. You might notice small changes at first, such as a darker area on the white of the eye or mild irritation, but some people have no clear early symptoms of scleromalacia perforans. Because it can progress with little pain or redness, any new change in the eye deserves prompt medical attention.
Unlike many other eye conditions, scleromalacia perforans often causes little or no pain. That lack of discomfort can make the problem easy to overlook, even when the white of the eye is thinning.
The white part of the eye may develop blue-gray or dark areas as deeper tissue shows through. Many living with scleromalacia perforans first notice this in the mirror or when someone else points it out.
Some people notice dryness, grittiness, or a mild feeling that something is in the eye rather than sharp pain. Day to day, it can feel like a contact lens is bothering the eye even when nothing is there.
Vision may become blurry if nearby parts of the eye are affected. Some may also notice glare, reduced sharpness, or trouble reading and driving.
How people usually first notice Scleromalacia perforans?
People usually first notice scleromalacia perforans not because of dramatic pain, but because the white of the eye starts to look unusually thin, bluish, or patchy, often in someone already living with long-standing rheumatoid arthritis or another inflammatory disease. One of the most important things about how scleromalacia perforans is first noticed is that it can be surprisingly quiet, with little or no redness or discomfort even as the eye wall slowly weakens, though some may notice mild irritation, dryness, or changes in vision. Because those early changes can be easy to miss, any new change in eye color, shape, or vision deserves prompt attention from an eye doctor.
Types of Scleromalacia perforans
Changes in the white part of the eye can be easy to miss at first, and many living with scleromalacia perforans do not have the intense pain people often expect with serious eye disease. Symptoms don’t always look the same for everyone. In practice, scleromalacia perforans is usually treated as one specific clinical form rather than a condition with several separate, widely accepted types of scleromalacia perforans. What varies most is how much thinning is present, how noticeable the eye changes are, and whether vision becomes affected.
Single form
Scleromalacia perforans is generally considered one recognized form of severe scleral thinning, not a disorder with its own standard subtypes. Some people notice little beyond a dark, bluish, or sunken-looking area on the white of the eye, while others develop more marked thinning, irritation, or vision changes as the eye becomes more fragile. It often occurs alongside autoimmune disease, especially rheumatoid arthritis, which can affect how quickly it progresses.
Can I slow down the onset of symptoms?
Not clearly through lifestyle alone: there is no strong evidence that diet, exercise, or supplements can meaningfully delay the start of scleromalacia perforans, but early and steady treatment of the underlying immune disease, most often rheumatoid arthritis, may lower the chance of this eye problem developing or getting worse. The best-supported steps are keeping that condition well controlled with your regular doctor, not smoking, and having regular eye exams so thinning of the white part of the eye can be found early; these steps may reduce risk, but they do not guarantee prevention. If you live with rheumatoid arthritis or another immune condition, staying engaged with your care team is the most useful and realistic way to protect your eyes.
What genetics can tell you about symptoms
For most people, genetics cannot clearly predict the symptoms of scleromalacia perforans itself, because this eye condition is usually linked to autoimmune disease, especially long-standing rheumatoid arthritis, rather than to a single gene change. Inherited differences may help explain why some people are more prone to autoimmune inflammation overall, which can indirectly affect who develops this condition and how severe the eye damage becomes. Even so, genes do not currently tell doctors with confidence which eye symptoms will appear first, how fast thinning of the white of the eye will progress, or exactly when it will begin.
Causes and risk factors
For many people, scleromalacia perforans develops after years of rheumatoid arthritis or another autoimmune disease. The main risk factors for scleromalacia perforans are long lasting inflammation, older age, and severe disease that is not well controlled. A family tendency toward autoimmune illness can add to the risk, and women are affected more often because rheumatoid arthritis is more common in women. Smoking and delayed treatment can worsen inflammation in the body, so they may make this eye problem more likely. Not everyone with the same risk develops the condition, so regular eye checks matter if you are living with rheumatoid arthritis.
What are the most common causes or risk factors?
Scleromalacia perforans is most often linked to long-lasting rheumatoid arthritis, a disease in which the body's immune system attacks its own tissues; the risk is higher when the arthritis has been severe for years or not well controlled. It can also happen, less often, with other autoimmune illnesses that cause ongoing inflammation, and it is seen more often in older adults, especially women, because these conditions are more common in those groups. There is no single known inherited cause, but a family tendency toward autoimmune disease may indirectly raise the risk.
Environmental and biological risk factors
Scleromalacia perforans is a rare eye condition most often linked to disease elsewhere in the body, especially autoimmune disease. The strongest known risks are biological rather than environmental. Doctors often group risks into internal (biological) and external (environmental). For scleromalacia perforans, clearly proven outside triggers are limited, while long-term immune-driven inflammation appears to play the main role.
The strongest risk factor is longstanding rheumatoid arthritis. Many people who develop scleromalacia perforans already have a history of rheumatoid disease that has been active for years.
Long-term immune system overactivity can slowly weaken the tough white outer coat of the eye. This risk is higher when autoimmune inflammation remains active or has been hard to control.
Less often, other autoimmune conditions that affect connective tissue or blood vessels can raise risk. These links are much less common than rheumatoid arthritis, but they are well recognized.
Scleromalacia perforans is seen more often in older adults than in children or younger adults. For many, this reflects the longer time an autoimmune disease has had to affect the body and eyes.
Genetic risk factors
Scleromalacia perforans is usually not inherited in a direct, one-gene way. Instead, the inherited part is most often a tendency toward autoimmune disease, especially longstanding rheumatoid arthritis, which can slowly thin the white wall of the eye. In practice, the genetic risk factors for scleromalacia perforans are mainly the genes that raise the chance of these immune conditions. Carrying a genetic change doesn’t guarantee the condition will appear.
No single gene: No one gene is known to directly cause scleromalacia perforans. Most inherited risk appears to work indirectly by increasing the chance of autoimmune disease that can affect the eye.
Family history: A family history of rheumatoid arthritis or related autoimmune disease can point to higher inherited risk. This does not mean someone will develop scleromalacia perforans, but it can make the underlying immune condition more likely.
HLA genes: Certain HLA immune-system genes are linked with a higher risk of rheumatoid arthritis. Because rheumatoid arthritis is the condition most strongly tied to scleromalacia perforans, these gene patterns may matter indirectly.
Immune control genes: Variants in genes that help control immune responses can also raise the chance of autoimmune disease. Their effect is usually small on its own and becomes more important when several risk genes are present together.
Autoimmune tendency: Some people inherit a broader tendency toward connective tissue disease or other autoimmune inflammation. In those cases, the risk of scleral thinning can vary depending on which underlying disease is present.
Lifestyle risk factors
Scleromalacia perforans is most often linked to poorly controlled systemic inflammation, especially in people with longstanding autoimmune disease. The main lifestyle-related influences are habits that can worsen inflammation, reduce treatment adherence, or delay recognition of eye damage. When people ask about lifestyle risk factors for scleromalacia perforans, the strongest links are usually indirect but still clinically important.
Smoking can intensify inflammatory disease activity and is associated with worse control of conditions such as rheumatoid arthritis, which can raise the chance of severe scleral damage. It may also reduce response to treatment and make eye complications harder to stabilize.
Skipping immunosuppressive or anti-inflammatory treatment can allow ongoing immune-driven tissue injury that increases the risk of scleral thinning. Inconsistent follow-up has a similar effect because worsening disease may go untreated for too long.
Ignoring new redness, irritation, dryness, or vision changes can delay diagnosis until thinning is advanced. Early ophthalmology review is important because this condition may progress with surprisingly little pain.
A diet pattern high in ultra-processed foods, refined sugars, and trans fats may contribute to higher systemic inflammatory burden. That can make the underlying autoimmune disease harder to control and may indirectly worsen ocular complications.
Risk prevention
Scleromalacia perforans is not always fully preventable, but the risk can often be lowered by managing the health problems that usually drive it, especially rheumatoid arthritis and other autoimmune disease. Many living with scleromalacia perforans have little pain at first, so regular eye care matters even when vision seems fine day to day. Prevention works best when combined with regular check-ups. Fast treatment of eye redness, new blurred vision, or other early symptoms of scleromalacia perforans may help prevent serious damage.
Good control of rheumatoid arthritis and similar autoimmune conditions can lower ongoing damage to the white outer coat of the eye. This often means staying on prescribed treatment and keeping regular visits with your rheumatology team.
Routine eye exams can catch thinning or silent inflammation before major vision problems develop. Many with scleromalacia perforans feel little discomfort, so monitoring is important even when the eyes seem normal.
New redness, blurry vision, light sensitivity, or a dark or blue-looking patch on the eye should be checked quickly. Early treatment may reduce the chance of worsening thinning or complications.
Dry, irritated eyes can make an already fragile eye surface more vulnerable. Using lubricating drops and treating eyelid or surface inflammation can help protect the eye.
Can you prevent Scleromalacia perforans?
Scleromalacia perforans usually cannot be fully prevented, because it often develops in people living with long-term rheumatoid arthritis or another illness where the immune system attacks the body’s own tissues. The clearest way to lower the risk is to keep those conditions well controlled with regular medical care and routine eye checkups, even if the eye does not hurt. Getting care quickly for vision changes, redness, or other new eye concerns may also help limit damage.
Transmission
Scleromalacia perforans is not contagious, so it does not spread from one person to another through touching, coughing, kissing, sex, or shared items such as towels, eye makeup, or contact lenses. It usually develops as part of an underlying autoimmune disease, most often rheumatoid arthritis, where the immune system slowly damages the white outer layer of the eye.
Many people ask whether Scleromalacia perforans is contagious, and the answer is no. For many living with Scleromalacia perforans, the main concern is managing the related autoimmune condition rather than any risk of passing the eye problem to someone else.
When to test your genes
For scleromalacia perforans, genetic testing is not a routine early-detection tool. What matters more is prompt eye evaluation if you have rheumatoid arthritis or new eye redness, pain, or vision changes, because care is guided by inflammation and autoimmune disease control rather than by a specific gene result.
Diagnosis
Scleromalacia perforans is usually diagnosed when an eye doctor notices painless thinning of the white part of the eye, often in someone living with rheumatoid arthritis or another inflammatory disease. Because it can progress quietly, the first clue may be a change seen during an eye exam rather than something you feel day to day. Doctors usually begin with a careful history and a close look at the eye to confirm the diagnosis of scleromalacia perforans and check how much of the eye wall is affected.
An ophthalmologist examines the surface of the eye and the deeper layers with a bright microscope called a slit lamp. In scleromalacia perforans, they look for marked thinning of the white of the eye, a bluish or dark appearance from deeper tissue showing through, and little or no redness despite severe damage.
The doctor asks about eye discomfort, vision changes, dryness, and whether symptoms have been absent even as the eye changes. They also ask about rheumatoid arthritis, vasculitis, or other autoimmune conditions because these often shape how scleromalacia perforans is diagnosed.
Blood tests may be ordered to look for autoimmune disease activity and signs of inflammation in the body. These tests do not diagnose the eye condition by themselves, but they can help find the underlying cause and rule out infection or other conditions.
If the thinning is severe or the view is limited, your provider may suggest ultrasound or specialized eye imaging to look closer. These scans help show how deep the thinning goes and whether nearby structures are involved.
How is Scleromalacia perforans diagnosed?
Scleromalacia perforans is usually diagnosed by an eye specialist during a full eye exam, especially by looking closely at the white part of the eye with a bright microscope to spot areas that have become very thin and may let the darker layer underneath show through. Doctors also ask about immune system conditions, especially rheumatoid arthritis, and often do blood tests to look for signs of an illness that could be causing the eye changes. Eye scans are sometimes used if a closer look is needed or if another eye problem needs to be ruled out, but genetic testing is not a standard part of diagnosis.
Stages of Scleromalacia perforans
Scleromalacia perforans does not have defined progression stages. This is because it usually is not described as moving through clear step-by-step phases; instead, the white wall of the eye gradually becomes thinner, sometimes with very few symptoms at first. Doctors usually start with a conversation about changes in vision, eye comfort, and autoimmune conditions such as rheumatoid arthritis, then examine the eye closely with a slit-lamp microscope. Because the early symptoms of scleromalacia perforans can be subtle or even absent, follow-up eye exams are important to monitor thinning, look for complications, and guide treatment.
Outlook and prognosis
The outlook for scleromalacia perforans is often one of slow but progressive thinning of the sclera, and while the eye can look alarming, pain is usually minimal or absent. Vision may remain fairly stable for a time, but prognosis depends on whether complications develop, such as severe scleral thinning, staphyloma formation, uveitis, glaucoma, cataract, or rarely globe perforation. Outcomes are also strongly influenced by control of the underlying systemic autoimmune disease, most commonly longstanding rheumatoid arthritis, because unchecked inflammation increases the risk of ocular damage and overall illness burden. With close ophthalmic follow-up and effective systemic immunosuppressive treatment when needed, many patients can avoid catastrophic eye complications, though structural scleral changes may be permanent. The condition itself is not usually a direct cause of death, but mortality can be higher in affected patients because it is associated with severe systemic vasculitic or autoimmune disease, which may carry serious complications beyond the eye.
Long-term effects
Scleromalacia perforans can have serious long-term effects on vision and eye health, even though it is often painless at first. Many people only realize something is wrong when the white of the eye looks bluish or dark because the outer wall of the eye has become very thin. Thinking about the long-term effects helps explain why regular eye follow-up matters, especially for people living with rheumatoid arthritis or similar inflammatory disease. The long-term picture is often shaped by how much thinning develops and whether other parts of the eye also become inflamed.
The main long-term effect of scleromalacia perforans is severe thinning of the white outer coat of the eye. Over time, this can leave the eye wall weak and more vulnerable to injury, even from relatively minor trauma.
Vision may stay normal early on, but some people develop blurred vision later if deeper eye structures become affected. In some cases, the damage can be permanent and lead to partial sight loss.
As the sclera becomes thinner, the shape of the eyeball can change. This may cause focusing problems or worsening astigmatism, so vision may no longer feel as sharp even with glasses.
Nearby corneal tissue can also become involved, which may lead to irritation, scarring, or worsening vision. For many, this can mean reading or driving becomes harder despite very little eye pain.
How is it to live with Scleromalacia perforans?
Living with scleromalacia perforans can feel unsettling because the white part of the eye slowly thins, often with surprisingly little pain, so many people do not realize how serious it is until vision changes or the eye becomes more fragile. Daily life may involve frequent eye and rheumatology visits, careful protection of the eyes from injury, and ongoing treatment of the underlying disease, often rheumatoid arthritis, because controlling body-wide inflammation is a big part of protecting sight. For family and close friends, the impact is usually less about caregiving every hour and more about helping with appointments, watching for new eye symptoms, and understanding that even when someone looks well, they may be carrying the stress of a condition that can threaten vision if it is not closely monitored.
Treatment and drugs
Scleromalacia perforans is treated by protecting the eye and, just as importantly, by calming the underlying immune disease that is causing the white part of the eye to thin. Treatment plans often combine several approaches. Many people with scleromalacia perforans need medicines that suppress an overactive immune system, often starting with steroid treatment and then adding longer-term drugs or biologic medicines, especially when rheumatoid arthritis or another autoimmune condition is present. Lubricating drops, careful monitoring by an eye specialist, and sometimes surgery or a patch graft may be needed if the eye becomes very thin or is at risk of rupture, so early treatment for scleromalacia perforans can help prevent serious vision-threatening damage.
Can you cure Scleromalacia perforans?
No, scleromalacia perforans usually cannot be cured, and the thinning in the white part of the eye that has already happened often cannot be reversed. Treatment is aimed at slowing or stopping further damage by controlling the underlying inflammatory disease, protecting the eye, and treating problems such as severe thinning or risk of a hole in the eye. In some people, surgery may be needed to strengthen the eye if the damage is advanced.
Non-drug treatment
Scleromalacia perforans can quietly thin the white wall of the eye, so care often focuses on protecting the eye and catching damage early. Many living with scleromalacia perforans have few day-to-day symptoms at first, which is why regular follow-up matters even when the eye is not painful. Beyond prescriptions, supportive therapies can include eye protection, close monitoring, surgery when thinning is severe, and coordinated care for the underlying autoimmune disease.
Regular visits with an eye specialist help track how much the sclera has thinned and whether nearby tissues are at risk. This is especially important because early symptoms of scleromalacia perforans may be mild or absent.
Wraparound glasses or safety goggles can help shield a fragile eye from accidental bumps, dust, and wind. For many, treatment begins not at the pharmacy, but with simple steps that lower the chance of injury.
Some may find it helps to avoid contact sports, heavy eye rubbing, or tasks with a higher risk of eye trauma. These changes do not reverse thinning, but they can help prevent a weak area from worsening.
If the eye wall becomes dangerously thin, surgery may be used to reinforce it with donor tissue or other graft material. Not every approach works the same way, and the exact procedure depends on where the thinning is and how severe it has become.
Your genes may have an impact on how drugs work for you
For people with scleromalacia perforans, treatment usually focuses on calming the underlying immune disease, often with medicines that lower harmful inflammation and protect the eye from further thinning. Small inherited differences in the body can change how fast some of these medicines are broken down or how strongly they work, so one person may improve steadily while another may need a different dose or a different medicine because of side effects or limited benefit. Even so, routine genetic testing is not a standard part of care for this eye condition, and doctors usually guide treatment by watching symptoms, eye exams, and how well the whole body disease is controlled.
Pharmacological treatments
Treatment for scleromalacia perforans usually focuses on calming the immune attack that is thinning the white of the eye, rather than treating pain or redness alone. Medication can feel like a big step, but early treatment for scleromalacia perforans may help lower the risk of further thinning and serious complications. Because this condition is often linked to autoimmune disease, many living with scleromalacia perforans also need treatment planned together with a rheumatologist.
Prednisone is often used to bring the disease under control more quickly. It lowers immune activity throughout the body, but it is usually not the best long-term plan because of side effects such as weight gain, higher blood sugar, and bone loss.
Methotrexate is a common first-choice long-term medicine when scleromalacia perforans is tied to rheumatoid arthritis or another autoimmune disease. It works more slowly than steroids, so it is often started alongside prednisone and then continued as the main control medicine.
Mycophenolate mofetil and azathioprine are steroid-sparing drugs that may be used when methotrexate is not suitable or does not work well enough. Not everyone responds to the same medication in the same way, so doctors may switch between these options based on benefit, side effects, and other health conditions.
Cyclophosphamide is a stronger immune-suppressing drug sometimes used for severe disease or when there is a high risk of eye damage. Because it can cause serious side effects, it is usually reserved for selected cases and needs close blood and urine monitoring.
Genetic influences
Scleromalacia perforans is not usually passed down as a single inherited eye disorder. It’s natural to ask whether family history plays a role, especially because this condition is often linked to rheumatoid arthritis and other autoimmune illnesses. In most cases, genetics seem to affect scleromalacia perforans indirectly by increasing a person’s tendency to develop autoimmune disease, which over time can damage and thin the white outer layer of the eye. A family history of rheumatoid arthritis or similar conditions may raise the chance of this background risk, but it does not mean someone will definitely develop scleromalacia perforans. There is no standard genetic test for scleromalacia perforans itself, so doctors usually focus more on personal history, family history, and signs of autoimmune disease than on a single gene result.
Is Scleromalacia perforans genetic?
Genetics are not thought to play a major direct role in scleromalacia perforans. It is usually linked to autoimmune disease, so inherited immune-system differences may slightly affect risk in some people.
Having a genetic risk is not necessarily a diagnosis
Genetic variants are a normal aspect of human biology and are common throughout the general population. Most do not have a direct effect on health and simply reflect natural human diversity. For many genes, carrying a variant associated with a condition points to a possible link rather than a definite diagnosis, especially when more than one gene and environmental factors are involved. In some situations, though, a single well-characterized variant in a particular gene can be enough to confirm a diagnosis.
Pharmacogenetics—how genetics influence drug effects
Because scleromalacia perforans is often linked to an autoimmune disease, treatment usually aims to calm the immune system and protect the eye, rather than treating the thinning with a single eye-specific drug. Not every difference in response is genetic, but inherited differences can affect how safely your body handles some medicines used for scleromalacia perforans, especially immune-suppressing treatments. For example, before using azathioprine, doctors may check genes called TPMT and NUDT15 because certain inherited changes can raise the risk of serious side effects, including very low blood counts. Genetics may also influence the underlying autoimmune illness, such as rheumatoid arthritis, which can shape the overall treatment plan. Even so, genes are only one part of the decision, and doctors also consider how severe the eye damage is, what other conditions you have, and how you have responded to medicines before. If you are looking into how genetics affect treatment for scleromalacia perforans, it is reasonable to ask whether any planned medication has a recommended genetic safety test before treatment begins.
Interactions with other conditions
People living with scleromalacia perforans often have another inflammatory illness in the background, most commonly rheumatoid arthritis, so eye changes may appear alongside joint pain, stiffness, or fatigue. The eye itself may stay surprisingly quiet, with little redness or pain, which can make the problem easy to miss while the underlying immune disease is active elsewhere in the body. Doctors call it a “comorbidity” when two conditions occur together, and in scleromalacia perforans this matters because the eye finding can be a sign that autoimmune inflammation has been affecting more than one tissue over time. Some may find that treatment decisions need to balance both conditions, since medicines that calm the immune system can help protect the eye but also need monitoring for side effects or infections. This is why people being checked for early symptoms of scleromalacia perforans are often also assessed for connective tissue diseases and other autoimmune conditions. Close follow-up between an eye specialist and the doctor managing the underlying illness can help reduce the risk of further thinning and vision-threatening complications.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
What other conditions can cause similar symptoms to Scleromalacia perforans?
Other conditions that can look similar include other types of scleritis, which is inflammation of the white part of the eye, episcleritis, which is a milder surface inflammation, and severe dry eye. Doctors may also need to rule out corneal ulcers or corneal thinning, infections, and other eye problems linked to autoimmune diseases such as rheumatoid arthritis or lupus, because these can also cause redness, irritation, or thinning of the eye.
History
People living with scleromalacia perforans often do not have the dramatic red, painful eye symptoms many expect with serious eye disease, which is one reason it was historically easy to miss. Earlier doctors mainly recognized it when they saw dark areas showing through a thinned white part of the eye, sometimes in someone who had long-standing joint disease and did not realize the eye was being affected.
Initially understood only through symptoms, later scleromalacia perforans was recognized as a distinct form of severe scleral thinning rather than just a vague complication of chronic eye inflammation. As medical science evolved, doctors became better at separating it from other causes of a red or damaged eye, including infections, injuries, and other inflammatory conditions. That mattered because scleromalacia perforans can progress quietly, and the early symptoms of scleromalacia perforans may be so mild that people notice only subtle changes, such as new sensitivity, blurred vision, or a change in the eye’s appearance in the mirror.
Over time, the history of scleromalacia perforans became closely tied to a broader understanding of autoimmune disease, especially rheumatoid arthritis. Researchers noticed that many affected people had inflammation elsewhere in the body, which helped shift thinking away from a problem limited to the eye alone. Later studies also supported a genetic contribution in some families and populations, although the history of the condition is mainly a story of improving clinical recognition rather than one single discovery.
In recent decades, imaging, earlier referral to eye specialists, and better treatment of immune-related disease have changed the outlook for many living with scleromalacia perforans. The condition is still uncommon, but it is now more likely to be recognized before severe damage occurs. Knowing this history helps explain why regular eye checks can matter so much for people with inflammatory joint disease, even when the eyes are not especially painful.